Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy

Douglas Jabs, Mark L Van Natta, John H. Kempen, Peter Reed Pavan, Jennifer I. Lim, Robert L. Murphy, Larry D. Hubbard

Research output: Contribution to journalArticle

Abstract

PURPOSE: To describe the characteristics of patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy (HAART). METHODS: Prospective cohort study. Baseline (enrollment) data were compared between patients with newly diagnosed cytomegalovirus retinitis (incident cases) and those with previously diagnosed cytomegalovirus retinitis (prevalent cases). RESULTS: As of December 31, 2000, 45 incident and 200 prevalent cases had been enrolled. Among prevalent cases, the median time from cytomegalovirus retinitis diagnosis was 2.9 years. Incident cases were more likely than prevalent cases to be women (35.4% vs 15.3%, P = .001), African American (45.4% vs 20.4%, P = .002), and uninsured (29.6% vs 7.6%, P <.001). Incident cases were less likely than prevalent cases to be on HAART (51.2% vs 77.6%, P = .001) and to have had an immunologic response to HAART (increase in CD4 + T-cell count to > 100 cells/μl) (12.2% vs 57.5%, P <.001). The median CD4 + T-cell count at enrollment among incident cases was 17 cells/μl and among prevalent cases was 159 cells/μl (P <.001). Immune recovery uveitis had been diagnosed in 15.5% of the prevalent cases. Sixty-three percent of prevalent cases were not on anticytomegalovirus therapy. CONCLUSIONS: There is a population of patients with previously diagnosed and longstanding cytomegalovirus retinitis who have experienced immune recovery as a consequence of HAART and are no longer receiving anticytomegalovirus therapy. There are demographic differences between incident and prevalent cases that may reflect the evolution of the AIDS epidemic and differences in utilization of health care services.

Original languageEnglish (US)
Pages (from-to)48-61
Number of pages14
JournalAmerican Journal of Ophthalmology
Volume133
Issue number1
DOIs
StatePublished - 2002

Fingerprint

Cytomegalovirus Retinitis
Highly Active Antiretroviral Therapy
Acquired Immunodeficiency Syndrome
Uveitis
CD4 Lymphocyte Count
African Americans
Health Services
Cohort Studies
Demography
Prospective Studies
T-Lymphocytes
Therapeutics
Population

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. / Jabs, Douglas; Van Natta, Mark L; Kempen, John H.; Pavan, Peter Reed; Lim, Jennifer I.; Murphy, Robert L.; Hubbard, Larry D.

In: American Journal of Ophthalmology, Vol. 133, No. 1, 2002, p. 48-61.

Research output: Contribution to journalArticle

Jabs, Douglas ; Van Natta, Mark L ; Kempen, John H. ; Pavan, Peter Reed ; Lim, Jennifer I. ; Murphy, Robert L. ; Hubbard, Larry D. / Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy. In: American Journal of Ophthalmology. 2002 ; Vol. 133, No. 1. pp. 48-61.
@article{fa39008f0986490396b18f94e4e56a9b,
title = "Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy",
abstract = "PURPOSE: To describe the characteristics of patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy (HAART). METHODS: Prospective cohort study. Baseline (enrollment) data were compared between patients with newly diagnosed cytomegalovirus retinitis (incident cases) and those with previously diagnosed cytomegalovirus retinitis (prevalent cases). RESULTS: As of December 31, 2000, 45 incident and 200 prevalent cases had been enrolled. Among prevalent cases, the median time from cytomegalovirus retinitis diagnosis was 2.9 years. Incident cases were more likely than prevalent cases to be women (35.4{\%} vs 15.3{\%}, P = .001), African American (45.4{\%} vs 20.4{\%}, P = .002), and uninsured (29.6{\%} vs 7.6{\%}, P <.001). Incident cases were less likely than prevalent cases to be on HAART (51.2{\%} vs 77.6{\%}, P = .001) and to have had an immunologic response to HAART (increase in CD4 + T-cell count to > 100 cells/μl) (12.2{\%} vs 57.5{\%}, P <.001). The median CD4 + T-cell count at enrollment among incident cases was 17 cells/μl and among prevalent cases was 159 cells/μl (P <.001). Immune recovery uveitis had been diagnosed in 15.5{\%} of the prevalent cases. Sixty-three percent of prevalent cases were not on anticytomegalovirus therapy. CONCLUSIONS: There is a population of patients with previously diagnosed and longstanding cytomegalovirus retinitis who have experienced immune recovery as a consequence of HAART and are no longer receiving anticytomegalovirus therapy. There are demographic differences between incident and prevalent cases that may reflect the evolution of the AIDS epidemic and differences in utilization of health care services.",
author = "Douglas Jabs and {Van Natta}, {Mark L} and Kempen, {John H.} and Pavan, {Peter Reed} and Lim, {Jennifer I.} and Murphy, {Robert L.} and Hubbard, {Larry D.}",
year = "2002",
doi = "10.1016/S0002-9394(01)01322-8",
language = "English (US)",
volume = "133",
pages = "48--61",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "1",

}

TY - JOUR

T1 - Characteristics of patients with cytomegalovirus retinitis in the era of highly active antiretroviral therapy

AU - Jabs, Douglas

AU - Van Natta, Mark L

AU - Kempen, John H.

AU - Pavan, Peter Reed

AU - Lim, Jennifer I.

AU - Murphy, Robert L.

AU - Hubbard, Larry D.

PY - 2002

Y1 - 2002

N2 - PURPOSE: To describe the characteristics of patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy (HAART). METHODS: Prospective cohort study. Baseline (enrollment) data were compared between patients with newly diagnosed cytomegalovirus retinitis (incident cases) and those with previously diagnosed cytomegalovirus retinitis (prevalent cases). RESULTS: As of December 31, 2000, 45 incident and 200 prevalent cases had been enrolled. Among prevalent cases, the median time from cytomegalovirus retinitis diagnosis was 2.9 years. Incident cases were more likely than prevalent cases to be women (35.4% vs 15.3%, P = .001), African American (45.4% vs 20.4%, P = .002), and uninsured (29.6% vs 7.6%, P <.001). Incident cases were less likely than prevalent cases to be on HAART (51.2% vs 77.6%, P = .001) and to have had an immunologic response to HAART (increase in CD4 + T-cell count to > 100 cells/μl) (12.2% vs 57.5%, P <.001). The median CD4 + T-cell count at enrollment among incident cases was 17 cells/μl and among prevalent cases was 159 cells/μl (P <.001). Immune recovery uveitis had been diagnosed in 15.5% of the prevalent cases. Sixty-three percent of prevalent cases were not on anticytomegalovirus therapy. CONCLUSIONS: There is a population of patients with previously diagnosed and longstanding cytomegalovirus retinitis who have experienced immune recovery as a consequence of HAART and are no longer receiving anticytomegalovirus therapy. There are demographic differences between incident and prevalent cases that may reflect the evolution of the AIDS epidemic and differences in utilization of health care services.

AB - PURPOSE: To describe the characteristics of patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy (HAART). METHODS: Prospective cohort study. Baseline (enrollment) data were compared between patients with newly diagnosed cytomegalovirus retinitis (incident cases) and those with previously diagnosed cytomegalovirus retinitis (prevalent cases). RESULTS: As of December 31, 2000, 45 incident and 200 prevalent cases had been enrolled. Among prevalent cases, the median time from cytomegalovirus retinitis diagnosis was 2.9 years. Incident cases were more likely than prevalent cases to be women (35.4% vs 15.3%, P = .001), African American (45.4% vs 20.4%, P = .002), and uninsured (29.6% vs 7.6%, P <.001). Incident cases were less likely than prevalent cases to be on HAART (51.2% vs 77.6%, P = .001) and to have had an immunologic response to HAART (increase in CD4 + T-cell count to > 100 cells/μl) (12.2% vs 57.5%, P <.001). The median CD4 + T-cell count at enrollment among incident cases was 17 cells/μl and among prevalent cases was 159 cells/μl (P <.001). Immune recovery uveitis had been diagnosed in 15.5% of the prevalent cases. Sixty-three percent of prevalent cases were not on anticytomegalovirus therapy. CONCLUSIONS: There is a population of patients with previously diagnosed and longstanding cytomegalovirus retinitis who have experienced immune recovery as a consequence of HAART and are no longer receiving anticytomegalovirus therapy. There are demographic differences between incident and prevalent cases that may reflect the evolution of the AIDS epidemic and differences in utilization of health care services.

UR - http://www.scopus.com/inward/record.url?scp=0036148962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036148962&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(01)01322-8

DO - 10.1016/S0002-9394(01)01322-8

M3 - Article

C2 - 11755839

AN - SCOPUS:0036148962

VL - 133

SP - 48

EP - 61

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 1

ER -